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Abstract
Background: Chronic hepatitis C (CHC) has emerged as a leading cause of cirrhosis in the U.S. and across the
world. To understand the role of apoptotic pathways in hepatitis C virus (HCV) infection, we studied the mRNA and
protein expression patterns of apoptosis-related genes in peripheral blood mononuclear cells (PBMC) obtained from
patients with HCV infection.
Methods: The present study included 50 subjects which plasma samples were positive for HCV, but negative for
human immunodeficiency virus (HIV) or hepatitis B virus (HBV). These cases were divided into four groups
according to METAVIR, a score-based analysis which helps to interpret a liver biopsy according to the degree of
inflammation and fibrosis. mRNA expression of the studied genes were analyzed by reverse transcription of
quantitative polymerase chain reaction (RT-qPCR) and protein levels, analyzed by ELISA, was also conducted. HCV
genotyping was also determined.
Results: HCV infection increased mRNA expression and protein synthesis of caspase 8 in group 1 by 3 fold and 4
fold, respectively (p < 0.05). In group 4 HCV infection increased mRNA expression and protein synthesis of caspase
9 by 2 fold and 1,5 fold, respectively (p < 0.05). Also, caspase 3 mRNA expression and protein synthesis had level
augumented by HCV infection in group 1 by 4 fold and 5 fold, respectively, and in group 4 by 6 fold and 7 fold,
respectively (p < 0.05).
Conclusions: HCV induces alteration at both genomic and protein levels of apoptosis markers involved with
extrinsic and intrinsic pathways.
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Background
Hepatitis C virus (HCV) is a major worldwide causative
pathogen of chronic hepatitis (CHC), cirrhosis, and
hepatocellular carcinoma [1]. Although the exact
mechanisms governing the elements of HCV pathogen-
esis, such as viral persistence, hepatocyte injury, and
hepatocarcinogenesis, are not fully understood, an accu-
mulating body of evidence suggests that apoptosis of
hepatocytes and peripheral blood mononuclear cells
(PBMCs) are significantly involved [2,3]. Apoptosis plays
a pivotal role in the maintenance of cellular homeostasis
through removal of aged, damaged, and hyperprolifera-
tive cells [4]. Resistance to apoptosis induced by various
stimuli is one of the most important factors in tumor
progression, as well as in resistance to cytotoxic therap-
ies [5]. In mammalian cells, apoptosis can be induced via
two major pathways. One is the death receptor pathway
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(extrinsic pathway), which is triggered by binding of FAS
ligand (FASLG) to FAS (CD95). This leads to activation
of caspase 8 (CASP8), which subsequently activates ef-
fector caspases 3, 6, and 7 (CASP3, CASP6, and CASP7)
[6-9]. The second apoptosis pathway (intrinsic pathway)
is induced by mitochondria in response to DNA damage,
oxidative stress, and viral proteins [2]. Mitochondrion-
dependent apoptosis is mediated by pro-apoptotic genes
(BAX, BAD, BAK, and others), whereas proteins like
BCL-2 and BCL-XL are anti-apoptotic. These proteins
converge at the mitochondrial permeability transition
pore, which regulates the release of apoptotic regulatory
proteins such as procaspase-9 and cytochrome c (CYCS)
[10].
Some studies have indicated that apoptosis of hepato-
cytes plays a significant role in the pathogenesis of HCV
infection [11-14], which is clinically recognized as liver
inflammation and fibrosis. To date, other alternative
sites of HCV replication, such as the PBMCs have been
recognized [15,16]. Therefore, CHC should be consid-
ered as a systemic disease rather than a local one [8].
Moreover, the HCV ability to directly infect those cells
might affect their function and down-modulate apop-
totic events, thereby allowing virus chronic replication
in target cells. However, the susceptibility of PBMCs to
apoptotic process in course of chronic HCV infection
has not yet been fully understood [13]. Therefore, the
aim of this work was to evaluate in PBMCs obtained
from chronic HCV patients the genomic and protein ex-
pression of 3, 8, 9 capases as well as Fas and, CYCS
which are involved with intrinsic and extrinsic apoptotic
pathways.
Results
Clinical aspects
The present study includes a total of 100 subjects, being
50 of them infected by HCV virus. These patients were
divided into four groups, according to the degree of fi-
brosis and inflammation, scored by METAVIR. In the
control group, 25 men and 25 women were selected.
Subjects with diabetes mellitus, hypertension, connective
tissue disease, other systemic diseases, acute or chronic
inflammatory disorders, infections, or hepatocellular car-
cinoma or other malignancy, as well as alcoholics and
smokers, were excluded. All patients signed informed
consents before inclusion and the ethical committee has
approved the protocol, which was in accordance with
the ethical guidelines of 1975 Declaration of Helsinki.
Table 1 shows the patients distribution according clinical
features.
Alterations in apoptotic markers in PBMCs
We first analyzed genes involved with the extrinsic
apoptosis pathway by measuring the expression levels of
FAS and CASP8 in PBMCs. In group 1, we observed a
7.5 fold increase in relative FAS expression compared to
control group, p < 0.05. However, FAS expression was
decreased by 5 fold in group 4 compared to control
group, p < 0.05 (Figure 1). We did not observe any sig-
nificant difference in FAS expression when comparing
groups 2 and 3 with the control group. We then ana-
lyzed CASP8 relative expression and observed a statisti-
cally significant increase of 3 fold change for group 1
when compared to control group, p < 0.05 (Figure 2a).
To validate these results, we decided to analyze
CASP8 at protein level and observed, by ELISA, that
only group 1 has CASP8 increased by 4 fold when com-
pared to control group, p < 0.05 (Figure 2b).
We next investigated whether intrinsic apoptosis could
possibly be involved in HCV infection through analysis
of relative expression of CASP9 and CYCS in PBMCs.
We observed that both were significantly increased in
group 4 when compared to the control group. Specific-
ally, there was an increase of 2 fold in CASP9 expression
and 5 fold change in CYCS expression (Figures 3a and
4). No differences were observed for groups 1, 2, or 3
when compared to control group. To confirm our
results, we also evaluated CASP9 protein levels in group
4 and the control group, and found that the difference
in mRNA expression was reflected in the protein levels.
Specifically, we observed a 1.5 fold increase in group 4
over the control group, p < 0.05 (Figure 3b).
Since CASP3 increased levels has already been asso-
ciated with activation of both the extrinsic and intrinsic
Table 1 Patients characteristics/variables
Parameter/Variables Mean ± S.D. Group 1 (n = 13) Group 2 (n = 13) Group 3 (n = 13) Group 4 (n =11) Control Group (n = 50)
ALT (mg/dl) 32.1 ± 4.7* 21.2 ± 2.8 19.9 ± 5.0 101.8 ± 5.0** 17.2 ± 6.1
AFP (ng/ml) 39.47 ± 0.2** 13.65 ± 0.1 16.82 ± 0.8** 56.76 ± 0.5** 10.03 ± 0.1
Viral load (IU/ml) 66.571 ± 3196 495.358 ± 2821 3.568.588 ± 2207 11.174.667 ±6385 -
Age (Mean) 47.8 ± 2.05 44.1 ± 1.58 46.9 ± 1.59 55.0 ± 2.98 45.0 ± 2.4
Male:female ratio 1:1 1.8:1 2.3:1 6.0:1 1:1
Genotype 1b/1a (73,13%) 3 (26,87%)
ALT, alanine aminotransferase (ALT normal range = Less than 20 mg/dl (Park et al., 2011); AFP, α-fetoprotein (AFP normal range = Less than 20 ng/ml (Sato et al.,
1993); (*) p< 0.05 vs. CTL; (**) p < 0.0001 vs. CTL.
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apoptosis pathways [2], we also decided to analyze this
caspase at genomic and protein level. mRNA expression
showed a 4 fold increase in group 1, p < 0.05 and 6 fold
increase for group 4 in CASP3 expression levels com-
pared to control group (Figure 5a).
To measure CASP3 protein levels we standardized an
“in-house” ELISA because a commercial assay kit for this
protein was not available. As expected, we found an aug-
ment in groups 1 (5 fold increase, p < 0.05) and 4 (7 fold
increase, p < 0.05) when compared to control group.
(Figure 5b).
Discussion
HCV often establishes itself as a persistent infection that
causes CHC, liver cirrhosis, and hepatocellular carcin-
oma, which are significant health problems throughout
the world [1]. Despite increasing knowledge of the mo-
lecular virology of HCV and associated apoptosis mar-
kers, the mechanisms of hepatocellular injury in HCV
infection are not fully understood. A delicate balance
normally exists in cells between antiapoptotic and proa-
poptotic regulators to ensure the proper survival and
turnover of different body cells [17].
In our study, we analyzed the influence of liver inflam-
mation and fibrosis in CHC patients on the gene
Figure 1 Analysis of mRNA expression of FAS in PBMCs by
qPCR.
Figure 2 a. Analysis of mRNA expression CASP8 in PBMCs by
qPCR. b. Analysis of protein levels of CASP8 in plasma.
Figure 3 a. Analysis of mRNA expression CASP9 in PBMCs by
qPCR. b. Analysis of protein levels of CASP9 in plasma.
Figure 4 Analysis of mRNA expression CYCS in PBMCs by qPCR.
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expression of FAS receptor, CASP3, CASP8, CASP9, and
CYCS in PBMCs. Further, we examined protein levels of
CASP3, CASP8, and CASP9 in plasma samples. These
factors are actively involved in apoptotic cell death, and
could indirectly indicate the susceptibility of cells to
apoptotic death. The apoptotic process seems to be the
host’s defense mechanism against viral infections, result-
ing in interruption of viral replication and elimination of
infected cells. FASL presented on activated CD8+ cyto-
toxic T cells interacts with overexpressed FAS receptors
to trigger apoptosis in infected hepatocytes and PBMCs.
The mechanisms for persistence of HCV infection are
complex because of divergent virus strategies for im-
mune system evasion. Under physiological conditions,
FAS-FASLG interactions protect immunological homeo-
stasis by regulating apoptosis of various immune cells
[18].
We observed significantly increased expression of FAS
receptor in PBMCs in patients from group 1. FAS recep-
tor expression may represent a self-limiting mechanism
of the immune response [19]. HCV genotype-dependent
differences in FAS expression cells have already been
described [20] and support the hypothesis that HCV
genotype 1 might induce apoptosis [21,22], this could
possibly be the reason for our results since genotype 1
was the most prevalent (73%) in our samples (Table 1).
In the other hand, for group 4, we observed a decrease
in FAS expression in PBMCs, and this was significantly
associated with cirrhosis and intense necroinflammation.
This result was supported by the hypothesis suggested
elsewhere [21] that reduced expression of FAS receptor
is associated with aggressive forms of hepatocellular car-
cinoma, especially in poorly differentiated tumors that
present portal vein or extracapsular invasion, this mech-
anism could possibly going on in our model. In group 1,
we observed a significant increase in CASP8 expression.
Activation of CASP8 via FAS receptor is an important
mechanistic initiator of apoptosis in physiological and
pathological conditions, and is extremely important in
the pathophysiology of CHC [18].
The activation of caspases can be triggered via death
receptors or by mitochondrial dysfunction, with the lat-
ter resulting in the release of CYCS [23]. The transloca-
tion of pro-apoptotic proteins to the mitochondria
results in the release of CYCS from outer and inner
mitochondrial membrane into the cytosol. In the cytosol,
CYCS forms a complex with apoptosis-activating factors,
leading to the activation of CASP9, which activates ef-
fector caspases.
Group 4 showed a significant increase of CASP9 and
CYCS , this found was already supported by at least an-
other group that reported same results associated with
significant increases in ALT and AFP levels [24]. The in-
direct markers of fibrosis reflect alterations in hepatic
function. A large number of indirect serum markers of
fibrosis have been tested over the past few years. They
mainly include AST and ALT levels, tested either alone
or in combination [25]. In our study, we observed sig-
nificantly increased ALT levels in group 4. The increased
ALT levels had been associated to mitochondrial injury,
which may be related to HCV infection, and is usually
predominant in liver cirrhosis [26-29]. AFP is also im-
portant in the diagnosis of hepatocellular carcinoma
[30]. In the present study, AFP was the most efficient
marker for patients in group 4 with liver cirrhosis, con-
firming the findings of Mohamed et al. [31]. With regard
to the correlation of viral load with biochemical mar-
kers, we found a positive and strong correlation of ALT
levels in group 4, and a positive and moderate correl-
ation with AFP levels in the same group [32]. In groups
2 and 3, we found similar levels of ALT and AFP when
compared to control group. Corroborating to these
results, CASP3, CASP8, and CASP9 mRNA expression
levels were also the same as in the control group.
CASP8 and CASP9 are the key initiator caspases acti-
vated through the death-receptor and mitochondrial
pathways, respectively [33,34], while CASP3 is the crit-
ical effector caspase of both pathways. In both groups 1
Figure 5 a. Analysis of mRNA expression CASP3 in PBMCs by
qPCR. b. Analysis of protein levels of CASP3 in plasma. Data were
expressed as the mean ± standard error of the mean. Experimental
and control groups were compared via the Student’s t-test and
ANOVA test. The significance level for a null hypothesis was set at
5% (p < 0.05).
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and 4, we observed a significant increase in CASP3 ex-
pression, suggesting a possibly activation of apoptosis.
Conclusions
In summary, the results of this study corroborate to the
body of evidence that HCV could induce the augment of
some apoptotic markers suggesting that perhaps apop-
tosis might be activated through both extrinsic and in-
trinsic pathways. CASP8 is normally activated through
the extrinsic pathway, which is triggered by tumor ne-
crosis factor receptor and FAS receptor [8]. In contrast,
CASP9 is activated through the intrinsic pathway, which
can be initiated by DNA damage and various extracellu-
lar stresses [33]. Both pathways induce CASP3, causing
its cleavage and ultimately apoptosis. This is in agree-
ment with our results showing increased CASP3 levels
in both groups 1 and 4, where the levels of CASP8 and
CASP9, respectively, were also increased. Nevertheless,
further investigations are necessary to evaluated if this
caspases are being activated in PBMCs of HCV infected
patients.
Methods
Patients and histological evaluation of biopsy samples
The present study was prospective and included 50 cases
with plasma samples that were positive for RNA-HCV
and negative for HIV/HBV by real-time PCR (RT-PCR).
Blood samples were collected from patients diagnosed at
the Unidade de Referência para Doenças Infecciosas Pre-
veníveis (Urdip) from Faculdade de Medicina do ABC,
São Paulo, between June and September 2010. Data
included age and gender. We also analyzed liver biopsies
(Metavir histologic score) [35], and liver function was
estimated by measuring alanine transaminase (ALT) and
α-fetoprotein (AFP) levels.
These cases were divided into 4 groups according to
the METAVIR scoring system after histological evalu-
ation of 50 paraffin-embedded liver specimens [35].
Liver histological staging was based on the degree of fi-
brosis and inflammatory activity, and the samples were
classified into 4 groups: group 1 (n = 13), fibrosis nor-
mal and necroinflamation absent; group 2 (n = 14), por-
tal tract fibrosis and mild necroinflamation; group 3
(n = 12), few septa and moderate necroinflammation;
and group 4 (n = 11), cirrhosis and intense necroinflam-
mation. We also collected 50 samples of healthy indivi-
duals for control group (n = 50).
Estimation of AFP and ALT levels
AFP levels were assessed using commercial available
ELISA assay kit (IBL America, Minneapolis, MN),
according to the manufacturer’s recommendations. The
cut-off value of AFP was set at 20 ng/mL, the most com-
monly used value [36,37].
Plasma ALT values were determined with a Hitachi
7050 automatic analyzer (Hitachi Corp., Tokyo, Japan)
using commercial available assay kits (Wako Chemicals).
The cut-off value for this assay was also set at 20 mg/
mL, as well established in the literature [38].
Detection of HIV, HCV, and HBV RNA/DNA by magnetic
bead isolation and polymerase chain reaction (PCR)
Total RNA/DNA was extracted and purified using mag-
netic bead technology with the appropriate kit (Chema-
gic Viral DNA/RNA kit). Three-hundred microliters of
plasma was used for each assay, and 100 μL of lysis buf-
fer was added to each sample. The samples were then
vortexed and incubated at room temperature for 10 min.
Subsequently, 150 μL of the magnetic beads was added,
and the mixture was incubated at room temperature for
20 min, with agitation every 10 min. Two-hundred
microliters of wash solution was then added, and again,
the tubes were vortexed to wash the magnetic beads. Fi-
nally, the beads were resuspended with 50 μL of elution
buffer. The isolated RNA/DNA (15 μL) was used in PCR
reactions for the detection of viral RNA (HIV or HCV)
or DNA (HBV). PCR was performed with primers select-
ive for HIV, HCV, and HBV (Table 2) [39].
When we analyzed presence of HIV and HCV, RNA
was reverse-transcribed into cDNA by the addition of
Superscript III PlatinumW One-Step reaction mix con-
taining all necessary reagents for amplification. Amplifi-
cation was performed using a 7500 Real-Time Sequence
Detection System (SDS; ABI Prism 7500; Applied
Table 2 Primer and probe sequences for the studied
genes
Primers and probe Sequences genes
Fas R 50- GGTGCAAGGGTCACAGTGTT-30
Fas F 50- TGAAGGACATGGCTTAGAAGTG-30
Caspase 3R 50- TGTCGGCATACTGTTTCAGCA-30
Caspase 3F 50- GCAGCAAACCTCAGGGAAAC-30
Caspase 8R 50- TCGCCTCGAGGACATCGCTCTC-30
Caspase 8F 50- CTGCTGGGGATGGCCACTGTG-30
Caspase 9R 50- TCTAAGCAGGAGATGAACAAAGG-30
Caspase 9F 50- GGACATCCAGCGGGCAGG-30
Cytochrome CR 50- TCTCCCCAGATGATGCCTTT-30
Cytochome CF 50- CAAGACTGGGCCAAATCTCC-3
HCV R 50- CGCGACCCAACACTACTC-30
HCV F 50- CGGGAGAGCCATAGTGGT-30
HCV PROBE FAM – TGCGGAACCGGTGAGTACACC - MGB
HBV R 50- GGACAAACGGGCAACATACC-30
HBV F: 50- ATGTGTCTGCGGCGTTTTATC-30
HBV PROBE: FAM – TCCTCTTCATCCTGCTGCTATGCCTCATCT - MGB
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Biosystems, CA). RT-PCR product accumulation was
monitored using a TaqMan probe [39,40].
Standardartization for detection of HCV viral load
Total RNA was extracted and purified using magnetic
bead technology with the appropriate kit (Chemagic
Viral DNA/RNA kit). The standard used for HCV real-
time RT-PCR was the commercial HCV RNA-positive
human plasma (Accurun 306; BBI Diagnostics, SeraCare,
MA) kit which was tested in triplicate. Ten-fold dilu-
tions of this standard were made down to 310 IU/mL by
using normal human plasma, and used in all runs to
generate standard curves. Dilutions of this standard were
tested with a total of 24 replicates for each point dilution
to determine the positive cut-off point or lower limit of
detection. RT-PCR product accumulation was monitored
using a TaqMan probe [39,40].
RNA extraction, cDNA synthesis, and quantitative RT-PCR
(qRTPCR) of FAS, CASP3, CASP8, CASP9, and CYCS in
PBMCs
Total RNA was purified from PBMCs by phenol and
guanidine isothiocyanate-cesium chloride method (Tri-
zol; Life Technologies). RNA was reverse-transcribed
into cDNA by addition of a mixture containing 0.5 mg/
mL oligo d(T), 10 mM DTT, 0.5 mM dNTPs (Pharmacia
Biotech, Sweden), and 200 U of reverse transcriptase
(SuperScript RT, Gibco-BRL). Real-time amplification
was performed using a 7500 Real-Time Sequence Detec-
tion System (SDS; ABI Prism 7500; Applied Biosystems,
CA). Reactions were cycled 40 times under the condi-
tions previously determined by conventional PCR. PCR
was performed with primers selective for FAS, CASP3,
CASP8, CASP9, and CYCS (Table 2). Results from these
experiments, per group, are reported as the relative ex-
pression normalized to the β-globin housekeeping gene
(Applied Biosystems, CA), used as endogenous control
[41,42]. RT-PCR product accumulation was monitored
using a Syber Green probe.
The cycle threshold (Ct) values were subtracted from
the housekeeping gene Ct value for each gene to yield
ΔCt values. These values were used to carry out statis-
tical comparisons. For graphical representations, the
fold-variation was determined using the 2-(ΔΔCt) method,
according to published protocols and the manufacturer’s
recommendations [43].
Analysis of CASP8 and CASP9 protein levels using
enzyme-linked immune sorbent assay (ELISA)
The plasma levels of CASP8 and CASP9 were assessed
using commercially available capture ELISA (IBL Amer-
ica, Minneapolis, MN). Both assays were performed
according to the manufacturer’s protocols. The optical
density of each sample was determined using an Ultra
Microplate Reader (EL808; Bio-Tek Instruments, VT)
and expressed as ng/mL [44,45].
Standardization and analysis of CASP3 protein levels
A microplate was pre-coated with a polyclonal avidin-
conjugated antibody specific for CASP3. Standard curve
was performed by adding 100uL of CASP3 peptide
(0–20 ng/mL) (Abcam Inc, Cambridge, MA) and sam-
ples were added to each well. Samples were then incu-
bated for 2 h at room temperature. After this incubation
period, samples were aspirated from the well and washed
4 times by filling each well with PBS-Tween 20. Next,
100 μL of antibody with streptavidin conjugated to
horseradish peroxidase (Abcam Inc, Cambridge, MA)
was added, and the mixture was incubated for 1 h at
room temperature before repeating the aspiration/wash
procedure. One hundred microliters of tetramethylben-
zidine and hydrogen peroxide were then added to each
well, and the mixture was incubated for 30 min at room
temperature before the addition of 100 μL of 1 N hydro-
chloric acid to each well. The optical density of each well
was determined using a microplate reader set to 450 nm.
To determine the CASP3 concentration (ng/mL) of each
sample, we first plotted the absorbance value on the y-axis
and extended a horizontal line to the standard curve. At
the point of intersection, a vertical line was extended to
the x-axis, and the corresponding value was the active
caspase-3 concentration.
HCV genotyping
After HCV RNA extraction using magnetic beads, sam-
ples were genotyped through sequencing of 50UTR in a
3500XL genetic analyzer (Applied Biosystems, CA,
USA). Primers sequences and protocol were performed
as described previously [46].
Statistical analysis
Data are expressed as the mean ± standard error of the
mean (SEM) values. Experimental and control groups
were compared using the Student’s t-test for protein
levels of CASP8 and CASP9, and ANOVA for the gene
expression analysis. The significance level for a null hy-
pothesis was set at 5% (p < 0.05). Pearson’s correlation
analysis in Microsoft Excel (Microsoft Corp., WA) was
used to determine the relationship between HCV viral
load and ALT/AFP levels [47].
The Research Ethics Committee of University Federal
of São Paulo/Sao Paulo Hospital examined and approved
this research project (no. 0080/10).
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